9 November 2022 ORYZON announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)
7 November 2022 ORYZON announces oral data presentation at the upcoming 64th American Society of Hematology annual conference
16 September 2022 ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
19 July 2022 ORYZON enters cooperative research and development agreement (CRADA) with U.S. National Cancer Institute to develop iadademstat in different cancers